Back to Media center

Media Releases

Select year

Sort by

84 items found

Kura Oncology and Kyowa Kirin report encouraging long-term results for ziftomenib / 7+3 combination in newly diagnosed AML

June 11, 2026

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

FDA Approves New Dosing Option for CRYSVITA^® (burosumab-twza) in Adults With XLH

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

CRYSVITA^® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program

Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

January 30, 2026

Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman

December 11, 2025

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

December 8, 2025

Showing 84 - 1 of 9